Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Single-Dose Antibiotic Clear all
Completed Phase 1 Interventional

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

NCT00678106
View directory record Official record
Conditions
Bacterial Infections
Interventions
Dalbavancin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2009 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis

NCT02447224
View directory record Official record
Conditions
Acute Uncomplicated Appendicitis
Interventions
1 gm IV ertapenem at enrollment, 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days, Appendectomy
Drug · Procedure
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 26, 2026, 4:35 AM EDT
Withdrawn Not applicable Interventional

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 26, 2026, 4:35 AM EDT
Recruiting Phase 4 Interventional

Prophylactic Antibiotics for Outpatient Urethral Bulking

NCT07501065
View directory record Official record
Conditions
Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
Interventions
Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 26, 2026, 4:35 AM EDT
Recruiting Phase 1 Interventional

Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure

NCT07490054
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
Biological · Drug
Lead sponsor
Melana Yuzefpolskaya, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization

NCT03061097
View directory record Official record
Conditions
Antibiotic Resistant Strain
Interventions
Autologous fecal microbiota transplant (Auto-FMP Enema), Placebo Enema Preparation
Biological · Other
Lead sponsor
Microbiome Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

NCT02771249
View directory record Official record
Conditions
HIV Infected Population With Latent Tuberculosis
Interventions
rifapentene (RPT), darunavir/cobicistat (DRV/c), Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02961764
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Usual Care, Dalbavancin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 26, 2026, 4:35 AM EDT
Enrolling by invitation Phase 3 Interventional

Antibiotic Prophylaxis in Rhinoplasty

NCT04194216
View directory record Official record
Conditions
Nasal Obstruction, Nasal Surgical Procedures
Interventions
Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg., Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional

Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial

NCT03283878
View directory record Official record
Conditions
Arthropathy of Knee, Antibiotic Prophylaxis
Interventions
Cefazolin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
San Francisco, California • Atlanta, Georgia • Towson, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

NCT04808414
View directory record Official record
Conditions
Bacterial Infections
Interventions
QPX9003 for IV Infusion, Placebo for IV infusion
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 26, 2026, 4:35 AM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 26, 2026, 4:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds

NCT04438174
View directory record Official record
Conditions
Wounds and Injuries
Interventions
Processed Amniotic Fluid, Standard of Care Wound Treatment Regimen
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 26, 2026, 4:35 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prospective Evaluation of Oral Antibiotics for Treatment of Shoulder PJI

NCT04636125
View directory record Official record
Conditions
Periprosthetic Infection, Oral Antibiotics, Revision Total Shoulder Arthroplasty
Interventions
Doxycycline 100 MG Oral Tablet
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

NCT01347034
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
External Beam Radiation Therapy (RT), Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

NCT03332732
View directory record Official record
Conditions
Bacterial Infections
Interventions
VNRX-5133, VNRX-5022, Metronidazole, Placebo
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 26, 2026, 4:35 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)

NCT00358462
View directory record Official record
Conditions
Urethritis
Interventions
Azithromycin, Doxycycline
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years and older · Male only
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

NCT01980095
View directory record Official record
Conditions
Dyspepsia, Helicobacter Pylori Infection
Interventions
RHB-105, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Anaheim, California • Chino, California • Jupiter, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 26, 2026, 4:35 AM EDT
Terminated Phase 1 Interventional

The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures

NCT04198129
View directory record Official record
Conditions
Jaw Fractures, Infection
Interventions
Antibiotic treatment (Unasyn or Cleocin), Antibiotic treatment (Augmentin or Cleocin), Control Group
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 26, 2026, 4:35 AM EDT
Terminated Phase 4 Interventional Results available

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

NCT03937999
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Bezlotoxumab
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microdialysis and Pharmacokinetic Study of TR-701

NCT00666601
View directory record Official record
Conditions
Healthy
Interventions
TR-700 (active moiety), TR-701 (pro-drug)
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Surgical Site Infection and Antibiotic Use Study

NCT04631185
View directory record Official record
Conditions
Surgical Site Infection, Breast Reconstruction, Antibiotic Use
Interventions
Single pre-operative dose of intravenous antibiotics with intraoperative redosing, One week of post-operative antibiotics
Drug
Lead sponsor
The Plastic Surgery Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 26, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

NCT01012089
View directory record Official record
Conditions
Chronic Kidney Disease, Bacterial Infection
Interventions
Daptomycin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 26, 2026, 4:35 AM EDT